Amendments to the Claims:

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-34. (Cancelled)

35. (Previously Presented) A method for the delivery of an immune response modifier (IRM) compound into or across a biological barrier comprising:

contacting a biological barrier with a microneedle device comprising at least one microneedle that penetrates the barrier by no more than 500 μm;

administering at least one IRM compound that is a TLR 7, and/or 8 agonist, selected from the group consisting of imidazoquinoline amines including, but not limited to, amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, aryl ether substituted imidazoquinoline amines, heterocyclic ether substituted imidazoquinoline amines, amido ether substituted imidazoquinoline amines, sulfonamido ether substituted imidazoquinoline amines, urea substituted imidazoquinoline ethers, and thioether substituted imidazoquinoline amines; tetrahydroimidazoquinoline amines including, but not limited to, amide substituted tetrahydroimidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline amines, aryl ether substituted tetrahydroimidazoquinoline amines, heterocyclic ether substituted tetrahydroimidazoquinoline amines, amido ether substituted tetrahydroimidazoquinoline amines, sulfonamido ether substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline ethers, and thioether substituted tetrahydroimidazoquinoline amines; imidazopyridine amines including, but not limited to, amide substituted imidazopyridines, sulfonamido substituted imidazopyridines, and urea substituted imidazopyridines; 1,2-bridged imidazoquinoline amines; 6,7-fused cycloalkylimidazopyridine amines; imidazonaphthyridine amines; tetrahydroimidazonaphthyridine amines; oxazoloquinoline amines; thiazoloquinoline amines; oxazolopyridine amines; thiazolopyridine amines; oxazolonaphthyridine amines; thiazolonaphthyridine amines; a pharmaceutically acceptable salt thereof; and combinations thereof, into or across the biological barrier; and

optionally administering a vaccine;

with the proviso that when the IRM compound is located in a reservoir or coating on the microneedle device along with the vaccine, the IRM compound is other than imiquimod or resiquimod.

36. (Original) The method of claim 35 wherein the biological barrier is the skin and the at least one IRM compound is delivered intracutaneously.

37. (Original) The method of claim 36 wherein contacting the skin with a microneedle device occurs prior to contacting the skin with at least one IRM compound.

38. (Original) The method of claim 36 wherein contacting the skin with at least one IRM compound comprises applying the at least one IRM compound topically to the skin.

39. (Original) The method of claim 38 wherein the at least one IRM compound is contained in a solution, ointment, gel, foam, or emulsion.

40. (Original) The method of claim 36 wherein contacting the skin with at least one IRM compound occurs prior to contacting the skin with a microneedle device.

41. (Original) The method of claim 40 wherein contacting the skin with at least one IRM compound comprises applying the at least one IRM compound topically to the skin.

42. (Original) The method of claim 41 wherein the at least one IRM compound is contained in a solution, ointment, gel, foam, or emulsion.

43. (Original) The method of claim 36 wherein contacting the skin with a microneedle device occurs coincident with contacting the skin with at least one IRM compound.

44. (Original) The method of claim 43 wherein the at least one IRM compound is coated on at least a portion of the microneedle device.

45. (Original) The method of claim 36 further comprising the intracutaneous administration of a vaccine.

46. (Original) The method of claim 35 wherein at least one IRM compound is a small molecule immune response modifier.

47. (Cancelled)

48. (Previously Presented) The method of claim 35 wherein the IRM is selected from the group consisting of amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, aryl ether substituted imidazoquinoline amines, heterocyclic ether substituted imidazoquinoline amines, amido ether substituted imidazoquinoline amines, sulfonamido ether substituted imidazoquinoline amines, urea substituted imidazoquinoline ethers, and thioether substituted imidazoquinoline amines; tetrahydroimidazoquinoline amines including, but not limited to, amide substituted tetrahydroimidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline amines, aryl ether substituted tetrahydroimidazoquinoline amines, heterocyclic ether substituted tetrahydroimidazoquinoline amines, amido ether substituted tetrahydroimidazoquinoline amines, sulfonamido ether substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline ethers, and thioether substituted tetrahydroimidazoquinoline amines; imidazopyridine amines including, but not limited to, amide substituted imidazopyridines, sulfonamido substituted imidazopyridines, and urea substituted imidazopyridines; 1,2-bridged imidazoquinoline amines; 6,7-fused cycloalkylimidazopyridine amines; imidazonaphthyridine amines; tetrahydroimidazonaphthyridine amines; oxazoloquinoline amines; thiazoloquinoline amines; oxazolopyridine amines; thiazolopyridine amines; oxazolonaphthyridine amines;

thiazolonaphthyridine amines; pharmaceutically acceptable salts thereof; and combinations thereof.

49-60. (Cancelled)